Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Kari G. Rabe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7313-1875; OpenAlex author ID A5078869044. Sources: OpenAlex.

Their work

Papers
58 (first author 6, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
127
Papers, trials and grants by year

2011: 4 papers · 2012: 4 papers · 2013: 6 papers · 2014: 3 papers · 2015: 4 papers · 2016: 4 papers · 2017: 2 papers · 2018: 4 papers · 2019: 3 papers · 2020: 5 papers · 2021: 5 papers · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 3 papers · 2026: 6 papers

Papers 50 of 58

  1. Germline Variants in Chronic Pancreatitis-Associated Genes and Risk of Pancreatic Ductal Adenocarcinoma. First author DOI 10.1016/j.cgh.2026.03.043↗
  2. Polygenic scores for risk of pancreatic ductal adenocarcinoma: evaluation of novel and published models. Co-author DOI 10.1038/s41698-026-01479-x↗
  3. Risk of Pancreatic Cancer in Glycemically Defined New-Onset Diabetes: A Prospective Cohort Study. Co-author DOI 10.1053/j.gastro.2025.06.025↗
  4. Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis. Co-author DOI 10.1093/jnci/djaf308↗
  5. Alterations in the CTRB2 gene and response to chemotherapy in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0343022↗
  6. Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals Co-author DOI 10.64898/2026.04.21.26351329↗
  7. Allelic effects on KLHL17 expression underlie a pancreatic cancer genome-wide association signal at chr1p36.33. Co-author DOI 10.1038/s41467-025-59109-2↗
  8. Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma. Co-author DOI 10.1530/erc-24-0142↗
  9. Bulk RNA-seq deconvolution heterogeneity across paired pancreatic cancer human samples. Co-author DOI 10.3389/fgene.2025.1662924↗
  10. Genome-Wide Analysis to Assess if Heavy Alcohol Consumption Modifies the Association between SNPs and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-24-0096↗
  11. Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germlin… Last author DOI 10.1001/jamaoncol.2023.0806↗
  12. Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization. Co-author DOI 10.1158/1055-9965.epi-23-0453↗
  13. Pancreatic cancer risk to siblings of probands in bilineal cancer settings. Co-author DOI 10.1016/j.gim.2022.01.016↗
  14. Influence of Cancer Susceptibility Gene Mutations and ABO Blood Group of Pancreatic Cancer Probands on Concomitant Risk to First-Degree Relatives. First author DOI 10.1158/1055-9965.epi-21-0745↗
  15. Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. Co-author DOI 10.1001/jamaoncol.2021.3701↗
  16. A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition. Co-author DOI 10.1016/j.jbc.2021.100634↗
  17. A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO. Co-author DOI 10.1038/s41416-021-01580-x↗
  18. Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Co-author DOI 10.1158/0008-5472.can-20-3267↗
  19. Shorter Treatment-Naïve Leukocyte Telomere Length is Associated with Poorer Overall Survival of Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-20-1279↗
  20. Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Co-author DOI 10.1158/0008-5472.can-20-0447↗
  21. Leukocyte Telomere Length and Its Interaction with Germline Variation in Telomere-Related Genes in Relation to Pancreatic Adenocarcinoma Risk. Co-author DOI 10.1158/1055-9965.epi-19-1597↗
  22. Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Co-author DOI 10.1158/1055-9965.epi-20-0275↗
  23. Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-20-0651↗
  24. Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-20-1788↗
  25. Pancreatic cancer and melanoma related perceptions and behaviors following disclosure of CDKN2A variant status as a research result. Co-author DOI 10.1038/s41436-019-0517-y↗
  26. Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of Probands' Susceptibility Gene Mutation Status. Co-author DOI 10.1093/jnci/djx272↗
  27. Analysis of Heritability and Genetic Architecture of Pancreatic Cancer: A PanC4 Study. Co-author DOI 10.1158/1055-9965.epi-18-1235↗
  28. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. Co-author DOI 10.1001/jama.2018.6228↗
  29. Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. Co-author DOI 10.1038/gim.2017.85↗
  30. Pancreatic cancer risk is modulated by inflammatory potential of diet and ABO genotype: a consortia-based evaluation and replication study. Co-author DOI 10.1093/carcin/bgy072↗
  31. CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Co-author DOI 10.1158/1055-9965.epi-17-1065↗
  32. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. Co-author DOI 10.1126/scitranslmed.aah5583↗
  33. Genetically Predicted Telomere Length is not Associated with Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-17-0100↗
  34. Pancreatic cancer: associations of inflammatory potential of diet, cigarette smoking and long-standing diabetes. Co-author DOI 10.1093/carcin/bgw022↗
  35. Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. First author DOI 10.1158/1055-9965.epi-15-1217↗
  36. Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-15-0402↗
  37. Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson. Co-author DOI 10.1200/jco.2015.63.3511↗
  38. Exposure to environmental chemicals and heavy metals, and risk of pancreatic cancer. Co-author DOI 10.1007/s10552-015-0652-y↗
  39. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. First author DOI 10.1038/gim.2014.153↗
  40. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Co-author DOI 10.1038/ng.3341↗
  41. Do variants associated with susceptibility to pancreatic cancer and type 2 diabetes reciprocally affect risk? First author DOI 10.1371/journal.pone.0117230↗
  42. Fatty acids found in dairy, protein and unsaturated fatty acids are associated with risk of pancreatic cancer in a case-control study. Co-author DOI 10.1002/ijc.28525↗
  43. Impact of diabetes mellitus on clinical outcomes in patients undergoing surgical resection for pancreatic cancer: a retrospective, cohort study. Co-author DOI 10.1038/ajg.2014.193↗
  44. Variants associated with susceptibility to pancreatic cancer and melanoma do not reciprocally affect risk. Co-author DOI 10.1158/1055-9965.epi-13-0627↗
  45. Polymorphisms in genes related to one-carbon metabolism are not related to pancreatic cancer in PanScan and PanC4. Co-author DOI 10.1007/s10552-012-0138-0↗
  46. Nutrients from fruit and vegetable consumption reduce the risk of pancreatic cancer. Co-author DOI 10.1007/s12029-012-9441-y↗
  47. Polymorphisms in metabolism/antioxidant genes may mediate the effect of dietary intake on pancreatic cancer risk. Co-author DOI 10.1097/mpa.0b013e3182968e00↗
  48. Meat-related mutagens and pancreatic cancer: null results from a clinic-based case-control study. Co-author DOI 10.1158/1055-9965.epi-13-0343↗
  49. Receptivity and preferences of pancreatic cancer family members for participating in lifestyle programs to reduce cancer risk. Co-author DOI 10.1186/1897-4287-11-3↗
  50. An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. Co-author DOI 10.1371/journal.pone.0072311↗

Closest collaborators

The 25 strongest of 127 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gloria M. Petersen · 38 shared papers, 2011–2023 · strength 2.63
  2. Samuel O. Antwi · 13 shared papers, 2015–2026 · strength 1.64
  3. Ann L. Oberg · 19 shared papers, 2011–2026 · strength 1.62
  4. Hugues Sicotte · 7 shared papers, 2011–2026 · strength 1.03
  5. Shruti Chandra · 4 shared papers, 2022–2025 · strength 0.72
  6. Robert R. McWilliams · 9 shared papers, 2011–2022 · strength 0.62
  7. Shounak Majumder · 3 shared papers, 2022–2025 · strength 0.58
  8. Rick J. Jansen · 6 shared papers, 2011–2025 · strength 0.49
  9. Ryan Michael Carr · 2 shared papers, 2025–2026 · strength 0.49
  10. Alison P. Klein · 7 shared papers, 2012–2021 · strength 0.44
  11. Steve Gallinger · 7 shared papers, 2012–2021 · strength 0.44
  12. Michael Goggins · 6 shared papers, 2015–2021 · strength 0.42
  13. Laufey Thora Amundadottir · 4 shared papers, 2014–2026 · strength 0.41
  14. Suresh T. Chari · 5 shared papers, 2011–2026 · strength 0.40
  15. Chunling Hu · 4 shared papers, 2018–2022 · strength 0.39
  16. Fergus Joseph Couch · 4 shared papers, 2018–2022 · strength 0.39
  17. Erica J. Childs · 5 shared papers, 2016–2021 · strength 0.38
  18. Sapna Syngal · 6 shared papers, 2012–2021 · strength 0.37
  19. Ralph H. Hruban · 5 shared papers, 2015–2021 · strength 0.35
  20. Amit Mahipal · 2 shared papers, 2021–2025 · strength 0.35
  21. Aminah Jatoi · 3 shared papers, 2017–2021 · strength 0.31
  22. Lisa A. Boardman · 3 shared papers, 2017–2021 · strength 0.31
  23. Rachael Z. Stolzenberg‐Solomon · 8 shared papers, 2011–2018 · strength 0.30
  24. Phil A. Hart · 3 shared papers, 2011–2026 · strength 0.29
  25. Jason W. Hoskins · 1 shared paper, 2026 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.